Faiza Zafar

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Rubén Niesvizky, David Jayabalan, Paul J. Christos et al. · Blood · 2007 · 183 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma

Tomer M. Mark, Jessica Stern, Jessica Furst et al. · Biology of Blood and Marrow Transplantation · 2008 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Jatin J. Shah, Rafat Abonour, Christina Gasparetto et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 93 citations

Medicine, Internal Medicine, Oncology +11

Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy

Rubén Niesvizky, Tara Naib, Paul J. Christos et al. · British Journal of Haematology · 2007 · 89 citations

Medicine, Hematology, Oncology +15

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

David S. Siegel, Gary J. Schiller, Christy Samaras et al. · Leukemia · 2020 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +12